March 22, 2021
Bavardian Nordic nets $31.2M deal with Public Health Agency of Canada
Bavarian Nordic got a $31.2million worth of Imvamune vaccines order from Public Health Agency of Canada (PHAC).
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
March 15, 2021
Roche buys genMak for $1.8 billion
Roche is buying GenMark at a price of US$ 24.05 per share in an all-cash transaction, the companies announced Monday agreement with a total transaction value of approximately US$ 1.8 billion.
January 28, 2021
Moderna confirms talking with the US on 100M doses of Cov-19 vaccine
After the US president’s Biden said the US Federal government would buy 100 million doses of the COVID-19 vaccine from Moderna and another 100 million from Pfizer, Moderna today confirmed that it is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
January 27, 2021
Teneobio cleared for it’s treatment of mCRPC in USA
Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021.
January 27, 2021
Promising therapy for menstrual pain tested by Myovant Sciences, Pfizer
Myovant Sciences and Pfizer said Monday that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination…
December 19, 2020
Moderna’s COVID-19 vaccine authorized in U.S.
U.S. FDA has authorized mRNA vaccine against COVID-19 for emergency use as total of 200 million doses ordered by the U.S government to date, with an option to purchase up to an additional 300 million doses, while approximately 20 million doses will be delivered by the end of December 2020.
December 18, 2020
Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States
Moderna has received positive recommendation in support of Emergency Use Authorization of its COVID-19 vaccine candidate in USA.
December 17, 2020
Merck’s supplemental BLA in priority review for Keytruda chemotherapy combo
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction
December 15, 2020
Moderna to supply Singapore with COVID-19 vaccine
Moderna has made a deal with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.
December 11, 2020
Pfizer, BioNTech get FDA’s support for potential first emergency use authorization for COVID-19 vaccine in the U.S.
Pfizer and BioNTech said that the FDA is expected to make a decision on Emergency Use Authorization in the coming days after giving a positive vote based on totality of scientific evidence presented by the companies, including Phase 3 efficacy and safety data, which would make BNT162b2 the first COVID-19 vaccine available in the U.S.